Science

James Davis: Ide-cel vs cilita-cel in R/R multiple myeloma

James Davis/X

Feb 23, 2025, 10:27

James Davis: Ide-cel vs cilita-cel in R/R multiple myeloma

James Davis, Assistant professor & malignant hematology pharmacist at MUSC Hollings Cancer Center, shared an article by Doris K. Hansen, et al. on X:

“In lieu of a head-to-head trial comparing ide-cel and cilta-cel (which we will never get), check out our study in Journal of Clinical Oncology comparing these products in over 600 patients.

Congrats Doris Hansen, Krina Patel, Surbhi Sidana, Danai Dima, Charlotte B Wagner.”

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Authors: Doris K. Hansen, et al.

James Davis: Ide-cel vs cilita-cel in R/R multiple myeloma

cancer CharlotteBWagner Ciltacabtagene Autoleucel Danai Dima Doris Hansen Doris K. Hansen fight against cancer Global fight against cancer idecabtagene vicleucel James Davis Journal of Clinical Oncology Krina Patel multiple myeloma MUSC Hollings Cancer Center OncoDaily Oncology Surbhi Sidana

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity